

IL-17A Polyclonal Antibody

catalog number: AN005920L

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description


Reactivity	Human
Immunogen	Recombinant Mouse IL-17A protein expressed by E.coli
Host	Rabbit
Isotype	IgG
Purification	Antigen Affinity Purification
Conjugation	Unconjugated
Buffer	PBS with 0.05% Proclin300, 1% protective protein and 50% glycerol, pH7.4

Applications

Recommended Dilution

IHC	1:150-1:300
------------	-------------

Data



Immunohistochemistry of paraffin-embedded Human lung cancer using IL-17A Polyclonal Antibody at dilution of 1:350.

Preparation & Storage

Storage	Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Shipping	The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended.

Background

Interleukin-17A (IL-17A), also known as CTLA-8, is a 15-20 kDa glycosylated cytokine that plays an important role in anti-microbial and chronic inflammation. The six IL-17 cytokines (IL-17A-F) are encoded by separate genes but adopt a conserved cystine knot fold. Mature rat IL-17A shares 60% and 89% amino acid sequence identity with human and mouse IL-17A, respectively. IL-17A is secreted by Th17 cells, γ/δ T cells, iNKT cells, NK cells, LT α cells, neutrophils, and intestinal Paneth cells. It forms disulfide-linked homodimers as well as disulfide-linked heterodimers with IL-17F. IL-17A exerts its effects through the transmembrane IL-17RA in complex with IL-17RC or IL-17RD. Both IL-17RA and IL-17RC are required for responsiveness to heterodimeric IL-17A/F. IL-17A promotes protective mucosal and epidermal inflammation in response to microbial infection. It induces chemokine production, neutrophil influx, and the production of antibacterial peptides. IL-17A/F likewise induces neutrophil migration, but IL-17F does not. IL-17A additionally enhances the production of inflammatory mediators by rheumatoid synovial fibroblasts and contributes to TNF- α induced shock. In contrast, it can protect against the progression of colitis by limiting chronic inflammation. IL-17A encourages the formation of autoreactive germinal centers and exacerbates the onset and progression of experimental models of autoimmunity. IL-17A has been shown to exert either tumorigenic or anti-tumor effects.

For Research Use Only